A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
Trial details
- Registry ID
- NCT05174416
- Phase
- Phase 3
The FDA approved Mavacamten (BMS-986327) on 28 Apr 2022.
Drug identity checked against registry records
Also recorded as BMS-986327; MYK-461
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCMNCT05174416 | LianBio LLC | Phase 3 | Completed | 2023-03-06Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-04-28Day | Mavacamten | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA214998", "applicant_as_listed_by_fda": "BRISTOL", "brand_names": ["CAMZYOS"], "active_ingredients": ["MAVACAMTEN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220428", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |